Considering Fedratinib or Ruxolitinib in the Frontline Setting for Treatment of Myelofibrosis
Ruben Mesa, MD, discusses his experience with fedratinib since its FDA approval for the treatment of patients with myelofibrosis. The agent is compared across trials with ruxolitinib, which has been approved for several years in this space.
Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses his experience with fedratinib (Inrebic) since its FDA approval for the treatment of patients with myelofibrosis (MF). The agent is compared across trials with ruxolitinib (Jakafi), which has been approved for several years in this space.
The most immediate impact for the approval of fedratinib is for the treatment of patients with MF who have not had an optimal response to ruxolitinib or who have lost their response and now may benefit from a new agent, says Mesa. However, there has not been a head-to-head comparison between these 2 agents. Both fedratinib and ruxolitinib have had very positive phase III studies, though their toxicity profiles are slightly different.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
